1. Home
  2. COGT vs BFS Comparison

COGT vs BFS Comparison

Compare COGT & BFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COGT
  • BFS
  • Stock Information
  • Founded
  • COGT 2014
  • BFS 1993
  • Country
  • COGT United States
  • BFS United States
  • Employees
  • COGT N/A
  • BFS N/A
  • Industry
  • COGT Biotechnology: Pharmaceutical Preparations
  • BFS Real Estate Investment Trusts
  • Sector
  • COGT Health Care
  • BFS Real Estate
  • Exchange
  • COGT Nasdaq
  • BFS Nasdaq
  • Market Cap
  • COGT 900.3M
  • BFS 975.8M
  • IPO Year
  • COGT 2018
  • BFS 1993
  • Fundamental
  • Price
  • COGT $7.91
  • BFS $40.29
  • Analyst Decision
  • COGT Buy
  • BFS Strong Buy
  • Analyst Count
  • COGT 6
  • BFS 1
  • Target Price
  • COGT $14.20
  • BFS $45.50
  • AVG Volume (30 Days)
  • COGT 1.7M
  • BFS 33.9K
  • Earning Date
  • COGT 11-12-2024
  • BFS 11-07-2024
  • Dividend Yield
  • COGT N/A
  • BFS 5.88%
  • EPS Growth
  • COGT N/A
  • BFS 10.72
  • EPS
  • COGT N/A
  • BFS 1.85
  • Revenue
  • COGT N/A
  • BFS $267,606,000.00
  • Revenue This Year
  • COGT N/A
  • BFS N/A
  • Revenue Next Year
  • COGT N/A
  • BFS $6.21
  • P/E Ratio
  • COGT N/A
  • BFS $21.77
  • Revenue Growth
  • COGT N/A
  • BFS 5.83
  • 52 Week Low
  • COGT $4.28
  • BFS $34.87
  • 52 Week High
  • COGT $12.61
  • BFS $42.39
  • Technical
  • Relative Strength Index (RSI)
  • COGT 32.81
  • BFS 50.47
  • Support Level
  • COGT $7.94
  • BFS $39.88
  • Resistance Level
  • COGT $8.56
  • BFS $40.47
  • Average True Range (ATR)
  • COGT 0.60
  • BFS 0.62
  • MACD
  • COGT -0.06
  • BFS -0.03
  • Stochastic Oscillator
  • COGT 9.60
  • BFS 40.93

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.

About BFS Saul Centers Inc.

Saul Centers Inc is a self-managed real estate investment trust which invests in, operates, and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.

Share on Social Networks: